By Infinium Global Research Aug, 2020
The Global Therapeutic Vaccines Market is expected to grow at a CAGR of 12.50% between 2019 and 2025 in terms of value. The major driving factor such as the increasing occurrence of cancer, cardiovascular diseases, HIV infection, and various chronic diseases are boosting the therapeutic vaccines market. The World Health Organization reports infectious diseases to kill more than 17 million people a year. 30 new diseases have emerged in the last 20 years. According to WHO, the common vaccine-preventable diseases include diphtheria, Haemophilus influenza serotype b infection, hepatitis B, measles, meningitis, mumps, pertussis, poliomyelitis, rubella, tetanus, tuberculosis, and yellow fever. In addition, an increase in funding from the government for vaccine development and growing awareness among people for severe disease are the key factors escalating the growth of the therapeutic vaccines market. Moreover, the unprecedented levels of urbanization and swelling populations of city dwellers inescapably pose greater risks of infectious disease transmission, which in turn, is likely to drive the growth of the market. However, the high cost associated with treatment is expected to hinder the growth of the therapeutic vaccines market. Moreover, various pharmaceutical players in this market are extensively researching on the research & development activities to develop novel vaccines for several diseases that may create growth opportunities for the therapeutic vaccines market in the near future.
The global therapeutic vaccines market is segmented based on Vaccines Type, Disease Indication, Administration, and by end-user. Vaccine type covered in the report includes autoimmune diseases vaccines, neurological disease vaccines, chronic disease vaccines and infectious diseases vaccines. Based on the market study the infectious diseases vaccines holds the largest share and has high growth potential, growing with a CAGR of 12.01% in the forecast period due to the rising population suffering from autoimmune diseases and infectious diseases. Based on the disease indication the segment is classified into pneumococcal disease, DTP, influenza, human papillomavirus, meningococcal disease, polio, hepatitis, MMR, varicella, and dengue. The DTP lead segment holds the largest share of 16.27% in 2018 owing to high incidences of Diphtheria, Tetanus, Pertussis among children, and a large number of government initiatives for the eradication of these diseases. By route of administration, the market is categorized in Intramuscular and subcutaneous administration, Oral Administration, and others. Based on the market study, the Intramuscular and subcutaneous administration lead the segment and is expected to grow with a significant CAGR of 12.92% in the forecast period as vaccines Hepatitis A, Human papillomavirus (HPV2 and HPV4) and Meningococcal polysaccharide (MPSV4) is administered by intramuscular and subcutaneous routes. Among the end-users, the pediatric segment holds the dominant share of 63.37% in the global therapeutic vaccines market.
Among the geographies, North America is the leading contributor to the therapeutic vaccines market. The U.S has the largest market share in the North America region. Developed medical and healthcare infrastructure and increasing funding for research and development activities are the few factors augmenting the growth in the North America region. On the other hand, the Asia-Pacific region is anticipated to be the fastest-growing market in the upcoming years owing to the increasing prevalence of various diseases, rising disposable income and rapidly growing aging population.